ASCO Annual Meeting 2022 Poster Report of Rivoceranib Phase II Study in Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)
This poster was presented at the 2022 ASCO Annual Meeting. It reported results of a Phase II study of Rivoceranib in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC). The Phase II multi-center study evaluated efficacy and safety in R/M ACC patients.
To read the full study report download the poster.